Diagnosis

Migraine

A syndrome of recurring headache:

  • Pulsating pain

  • Unilateral

  • Frontotemporal and ocular region

  • Moderate-to-severe intensity

  • Period: 4–72 hours

  • Neurological symptoms:

    • Nausea

    • Vomiting

    • Aura (20%) [fbw]

    • Horner syndrome

    • Sensory hypersensitivity: light, sound, or movement [bfk]

  • Resistant migraine:

    • Failed at least 3 classes of migraine preventatives

    • 8 debilitating headache days per month for 3 consecutive months

  • Refractory migraine:

    • Failed all of the available preventatives

    • 8 debilitating headache days per month for 6 consecutive months

Etiology

Cause [fbw]

Pathophysiology [9vo]

  1. A premonitory phase:

    • Yawning, mood changes, lethargy, neck stiffness, sensitivity to light and sound, restlessness, difficulty focusing vision, feeling cold, cravings, sweating, increased energy, thirst, and edema

  2. Transient neurological symptoms (migraine aura)

    • Positive symptoms (scintillating scotoma, bright lines or shapes, tinnitus, noises, paresthesias, allodynia, or rhythmic movements)

    • Negative symptoms (visual field defects, hearing, sensation, or movement)

  3. Headache lasting from hours to days:

    • Unilateral, pulsating pain with nausea, vomiting, photophobia, phonophobia, rhinorrhea, lachrymation, allodynia, and osmophobia

  4. Postdrome phase: movement-vulnerable headache, exhaustion, dizziness, difficulty concentrating, and euphoria

Risk factor [bfk][fbw]

Epidemiology

Incidence per 100.000 [bfk][s9o][9os][cgo][gai][2vq][vt9]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Agitation, Anopsia, Anorexia, Aphasia, Bilateral hemianopsia, Confusion, Depression, Dizziness, Dysarthria, Headache, Lethargy, Miosis, Muscle weakness, Osmophobia, Paresthesia, Phonophobia, Photophobia, Ptosis, Scotoma, Vertigo, Vomiting

Clinical findings

Conjunctival injection

Anamneses

None listed.

Localized findings

Pain
Radiates
Regio frontalisRegio temporalisRegio parietalisRegio occipitalis
Onset
Acute (minutes)Subacute (hours)
Pattern
Constant
Provoked by
DefecationActivityCoughingSneezing
Quality
Pressing
Severity
Moderate (4-7)

Approach

Treatment

  1. Non-pharmacological: [fbw]

    • Reduction of triggers: lack of sleep, fatigue, stress, certain foods (alcohol, caffein, chocolate, aspartame, citrus fruits, bananas, avocados, dried fruit, nuts and soy

    • Cognitive-behavioral therapy

  2. Acute phase: [fbw]

    • Selective serotonin receptor agonists (triptans)

    • Serotonin agonists (ditans, lasmiditan)

    • Calcitonin gene-related peptide receptor antagonists (rimegepant, ubrogepant)

    • Ergot alkaloids (ergotamine, dihydroergotamine)

    • Analgesics

    • NSAIDs

    • Antiemetics

  3. Prophylactic treatment if >2 attacks per month or duration of attacks >24 hours or symptomatic medications are ineffective: [fbw]

    • Antiepileptic drugs

    • Beta blockers

    • Tricyclic antidepressants

    • Calcium channel blockers

    • SSRIs

    • NSAIDs

    • Serotonin antagonists

    • Botulinum toxin

    • CGRP inhibitors

Differential diagnoses

Benign paroxysmal positional vertigo, Brain abscess, Brain tumor, Carotid artery dissection, Cerebral aneurysm, Cerebral venous sinus thrombosis, Cluster headache, Encephalitis, Intracerebral hemorrhage, Labyrinthitis, Medication-overuse headache, Meniere disease, Meningitis, Subarachnoid hemorrhage, Temporal arteritis, Tension headache


References

[1] https://emedicine.medscape.com/article/1142556

[2] Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safiri S. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605.

[3] Pescador Ruschel MA, De Jesus O. Migraine Headache. [Updated 2024 Jul 5]: https://www.ncbi.nlm.nih.gov/books/NBK560787/

[4] Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, Kaufman J, Collins G, Dai H, Bragazzi NL, Kolahi AA. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022 Feb 1;163(2):e293-e309.

[5] Fan, L., Wu, Y., Wei, J. et al. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain 24, 79 (2023).

[6] Stovner, Lars Jacob et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, Volume 17, Issue 11, 954 - 976.

[7] Yang Y, Cao Y. Rising trends in the burden of migraine and tension-type headache among adolescents and young adults globally, 1990 to 2019. J Headache Pain. 2023 Jul 27;24(1):94.

[8] Fan Z, Kang J, Li W, Wang Z, Qiao H, Xu F. Trends in migraine incidence among women of childbearing age from 1990 to 2019 and the prediction for 2030: an analysis of national data in China. J Headache Pain. 2023 Nov 27;24(1):158.

[9] Stang PE, Yanagihara PA, Swanson JW, Beard CM, O'Fallon WM, Guess HA, Melton LJ 3rd. Incidence of migraine headache: a population-based study in Olmsted County, Minnesota. Neurology. 1992 Sep;42(9):1657-62.

[10] Wang, Y., Huang, X., Yue, S., Liu, J., Li, S., Ma, H., … Wu, J. (2022). Secular Trends in the Incidence of Migraine in China from 1990 to 2019: A Joinpoint and Age–Period–Cohort Analysis. Journal of Pain Research, 15, 137–146.

Scroll to top